Microsoft Word - S_2019_GRC-02_025_S43 Share Acquisition_EN Page 1 – Translation – GRC-02/2019/025 11 December 2019 Subject: Report of the Asset Acquisition To: President The Stock Exchange of
18,688.48 27,642.26 (8,953.78) (32.39) Administrative expenses 913.70 745.76 167.94 22.52 Total expenses 19,602.18 28,388.02 (8,785.84) (30.95) Profit before share of profit (loss) from investments in
21.00 34.02% Administrative expenses 35.21 32.44 2.77 8.54% Financial costs 0.45 0.02 0.43 2,150.00% Share of profit (loss) of associates (0.17) (0.17) 0 0.00% Profit before income tax expenses 42.15
expenses incurred from the subsidiary’s share acquisition ie. loan , advisory and lawyer fees for an aggregated amount of THB 2.3 million. Earnings before interest, taxes and depreciation (“EBITDA”) EBITDA
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
share acquisition which has been drawdown in 2Q’18 was paid off in 2Q19. Net Profit Net profit attributable to the Company has increased by 10% yoy. despite the aforementioned extra cost & expenses for
ordinary shares of 1,437,456,000 shares under IPO with a par value of THB 5.00 per share and IPO price at THB 5.20 per share. Nevertheless, the Company intends to maintain its shareholding in SHR at 60% of
average selling price decreased considerably due to slowdown in Thai economy, strengthening of Thai Baht, and surge in imports of Alloy Steel and Galvanised HRC post expiry of safeguard duties. While total